BackTaiGen Biopharmaceuticals Holdings Limited Overview

TaiGen Biopharmaceuticals Holdings Limited Total Current Liabilities

Track TaiGen Biopharmaceuticals Holdings Limited's total current liabilities ($31M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$31.49M
↓ 60.28% YoYΔ $-47.80M vs prior year quarter

Peer trimmed avg / median

Loading

TaiGen Biopharmaceuticals Holdings Limited Total Current Liabilities History

Loading

TaiGen Biopharmaceuticals Holdings Limited vs. peers: Total Current Liabilities Comparison

Loading

TaiGen Biopharmaceuticals Holdings Limited Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

TaiGen Biopharmaceuticals Holdings Limited (4157.TWO) FAQ

TaiGen Biopharmaceuticals Holdings Limited's total current liabilities stands at $31M as of June 2026. That compares with $79M in the prior-year period — down 60.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

TaiGen Biopharmaceuticals Holdings Limited reported $31M in total current liabilities versus $79M a year earlier — a 60.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $79M in the prior-year period — down 60.3% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how TaiGen Biopharmaceuticals Holdings Limited's total current liabilities evolved across reporting periods, while the comparison chart places 4157.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. TaiGen Biopharmaceuticals Holdings Limited's reading of $31M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.